Blue Earth Therapeutics Limited develops targeted radiopharmaceutical therapies, such as lutetium‑17 Sign up to read more
| Allotment | Filed | Share Class | Round Size | Round Type |
|---|---|---|---|---|
2025-12-12 | £15.8M |
| Shareholder | Share class | Shares | Holding |
|---|---|---|---|
| BRACCO HORIZONS LIMITEDCORP | ORDINARY, SERIES A PREFERRED | 113,641,060 | 72.4% |
| 8888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 88888888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 888888888888888888 | 8888888888 | 888888 | 8888 |
| 8888888888888 | 88888888 | 888888 | 8888 |
| 8888888888888 | 88888888 | 888888 | 8888 |
11 more shareholders on file , sign up free to see.
Companies with the most similar business descriptions.
Capital raised per employee divides the equity BLUE EARTH THERAPEUTICS LIMITED raised in the last six months by the headcount in its most recent filed accounts. It is a rough read on how capital-intensive the business is: a high figure means the company is raising a lot relative to the number of people it employs, which is typical of hardware, biotech and other research-heavy businesses. Headcount comes from annual accounts and so lags the funding date, often by a year or more.
A share class is a category of shares carrying its own rights over voting, dividends and what happens to the money if the company is sold or wound up. UK companies typically issue Ordinary shares to founders and employees, then create a new Preferred class at each funding round, giving investors priority on proceeds ahead of the Ordinary holders. BLUE EARTH THERAPEUTICS LIMITED has 3 distinct classes on file at Companies House; the rights attached to each are reproduced below as filed.
THE GROWTH SHARES DO NOT HAVE VOTING OR DIVIDEND RIGHTS, BUT DO HAVE DISTRIBUTION RIGHTS (INCLUDING ON WINDING UP). ON A LIQUIDATION OR SALE, THE GROWTH SHARES RANK BEHIND (1) THE SERIES A PREFERRED SHARES, AS TO THE RETURN OF AN AMOUNT EQUAL TO THE GREATER OF (I) THE “PREFERENCE AMOUNT” (AS DEFINED IN THE ARTICLES) OR (II) AN AMOUNT RECEIVABLE IF CONVERTED INTO ORDINARY SHARES AT THE CONVERSION RATIO; AND (2) THE ORDINARY SHARES, AS TO THE RETURN OF AN AMOUNT EQUAL TO THE HURDLE AMOUNT (AS DEFINED IN THE ARTICLES); BUT THEREAFTER ANY REMAINING ASSETS ARE DISTRIBUTED PRO RATA TO HOLDERS OF ORDINARY SHARES AND GROWTH SHARES AS IF THEY CONSTITUTED ONE CLASS OF SHARE. THE GROWTH SHARES MAY AT ELECTION OF THE BOARD AND IN SOME CIRCUMSTANCES AUTOMATICALLY BE CONVERTED INTO ORDINARY SHARES.
THE ORDINARY SHARES HAVE FULL VOTING, DIVIDEND AND DISTRIBUTION RIGHTS (INCLUDING ON WINDING UP). ON A LIQUIDATION OR SALE, THE ORDINARY SHARES RANK BEHIND THE SERIES A PREFERRED SHARES AS TO THE RETURN OF AN AMOUNT EQUAL TO THE GREATER OF (I) THE “PREFERENCE AMOUNT” (AS DEFINED IN THE ARTICLES) OR (II) AN AMOUNT RECEIVABLE IF CONVERTED INTO ORDINARY SHARES AT THE CONVERSION RATIO; BUT THEREAFTER, THE ORDINARY SHARES RECEIVE AN AMOUNT EQUAL TO THE HURDLE AMOUNT (AS DEFINED IN THE ARTICLES) PER ORDINARY SHARE; AND THEREAFTER ANY REMAINING ASSETS ARE DISTRIBUTED PRO RATA TO HOLDERS OF ORDINARY SHARES AND GROWTH SHARES AS IF THEY CONSTITUTED ONE CLASS OF SHARE. THE ORDINARY SHARES DO NOT CONFER RIGHTS OF REDEMPTION.
THE SERIES A PREFERRED SHARES HAVE FULL VOTING, DIVIDEND AND DISTRIBUTION RIGHTS (INCLUDING ON WINDING UP). ON A LIQUIDATION OR SALE, THE SERIES A PREFERRED SHARES RANK IN PRIORITY TO THE ORDINARY SHARES AND GROWTH SHARES AS TO THE RETURN OF AN AMOUNT EQUAL TO THE GREATER OF (I) THE “PREFERENCE AMOUNT” (AS DEFINED IN THE ARTICLES) OR (II) AN AMOUNT RECEIVABLE IF CONVERTED INTO ORDINARY SHARES AT THE CONVERSION RATIO. THE SERIES A PREFERRED SHARES MAY AT ELECTION OF THE HOLDER AND IN SOME CIRCUMSTANCES AUTOMATICALLY BE CONVERTED INTO ORDINARY SHARES.
These are the directors and secretaries who have left BLUE EARTH THERAPEUTICS LIMITED. A resignation is filed with Companies House on form TM01 and the date below is the date the officer's appointment ended, not the date it was filed. Departures matter for reading a company's history: a founder leaving shortly after a funding round, or several directors resigning at once, is often the visible trace of a change of control or a restructure.